What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types
Metrics: PDF 1209 views | Full Text 2631 views | ?
Christian Mark Farag1, Ryan Antar1, Sinan Akosman1, Matthew Ng2 and Michael J. Whalen1
1 Department of Urology, George Washington University School of Medicine, Washington, DC 20052, USA
2 Department of Surgery, George Washington University School of Medicine, Washington, DC 20052, USA
|Christian Mark Farag,||email:||[email protected]|
Keywords: HALP score; biomarker; prognosis; cancer; survival
Received: December 25, 2022 Accepted: January 23, 2023 Published: February 25, 2023
Since its inception, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has gained attention as a new prognostic biomarker to predict several clinical outcomes in a multitude of cancers. In our review, we searched PubMed for articles between the first paper on HALP in 2015 through September 2022, yielding 32 studies in total that evaluated HALP's association with various cancers, including Gastric, Colorectal, Bladder, Prostate, Kidney, Esophageal, Pharyngeal, Lung, Breast, and Cervical cancers, among others. This review highlights the collective association HALP has with demographic factors such as age and sex in addition to TNM staging, grade, and tumor size. Furthermore, this review summarizes HALP's prognostic ability to predict overall survival, progression-free survival, recurrence-free survival, among other outcomes. In some studies, HALP has also been able to predict response to immunotherapy and chemotherapy.
This review article also aims to serve as a comprehensive and encyclopedic report on the literature that has evaluated HALP as a biomarker in various cancers, highlighting the heterogeneity surrounding HALP's utilization. Because HALP requires only a complete blood count and albumin - already routinely collected for cancer patients - HALP shows potential as a cost-effective biomarker to aid clinicians in improving outcomes for immuno-nutritionally deficient patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.